| Document and Entity Information - shares | 9 Months Ended | |
| Sep. 30, 2016 | Nov. 16, 2016 | |
| Document and Entity Information [Abstract] | ||
| Entity Registrant Name | OphthaliX, Inc. | |
| Entity Central Index Key | 1,218,683 | |
| Amendment Flag | false | |
| Current Fiscal Year End Date | --12-31 | |
| Document Type | 10-Q | |
| Document Period End Date | Sep. 30, 2016 | |
| Document Fiscal Year Focus | 2,016 | |
| Document Fiscal Period Focus | Q3 | |
| Entity Filer Category | Smaller Reporting Company | |
| Entity Common Stock, Shares Outstanding | 10,441,251 |
| Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2016 | Dec. 31, 2015 | |
| CURRENT ASSETS: | |||
| Cash and cash equivalents | $ 15 | $ 42 | |
| Investment in Parent Company (marketable securities) | 596 | 658 | |
| Other accounts receivable | 11 | ||
| Total assets | 622 | 700 | |
| CURRENT LIABILITIES: | |||
| Related company | 4,188 | 3,690 | |
| Other accounts payable and accrued expenses | 313 | 291 | |
| Total current liabilities | 4,501 | 3,981 | |
| NON-CURRENT LIABILITIES: | |||
| Derivative related to Service Agreement | [1] | ||
| Share capital | |||
| Preferred Stock - Authorized: 1,000,000 shares at September 30, 2016 and December 31, 2015, respectively; Issued and Outstanding: 0 shares at September 30, 2016 and December 31, 2015 | |||
| Common Stock of$0.001 par value - Authorized:100,000,000 shares at September 30, 2016 and December 31, 2015, respectively; Issued and Outstanding: 10,441,251 shares at September 30, 2016 and December 31, 2015, respectively | 10 | 10 | |
| Additional Paid-in capital | 5,519 | 5,516 | |
| Accumulated other comprehensive income | (96) | (34) | |
| Accumulated deficit | (9,312) | (8,773) | |
| Totalstockholders' deficiency | (3,879) | (3,281) | |
| Total liabilities and stockholders' deficiency | $ 622 | $ 700 | |
| [1] | Represents an amount lower than $ 1 | ||
| Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares | Sep. 30, 2016 | Dec. 31, 2015 |
| Statement of Financial Position [Abstract] | ||
| Preferred stock, shares authorized | 1,000,000 | 1,000,000 |
| Preferred stock, shares issued | 0 | 0 |
| Preferred stock, shares outstanding | 0 | 0 |
| Common stock, par value | $ 0.001 | $ 0.001 |
| Common stock, shares authorized | 100,000,000 | 100,000,000 |
| Common stock, shares issued | 10,441,251 | 10,441,251 |
| Common stock, shares outstanding | 10,441,251 | 10,441,251 |
| Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
| Sep. 30, 2016 | Sep. 30, 2015 | Sep. 30, 2016 | Sep. 30, 2015 | Dec. 31, 2015 | |
| Operating expenses: | |||||
| Research and development | $ 30 | $ 247 | $ 158 | $ 550 | $ 812 |
| General and administrative | 185 | 85 | 293 | 270 | 573 |
| Total operating expenses | 215 | 332 | 451 | 820 | 1,385 |
| Financial expenses, net | 29 | 21 | 88 | 61 | 92 |
| Net loss | $ 244 | $ 353 | $ 539 | $ 881 | $ 1,477 |
| Net loss per share: | |||||
| Basic and diluted loss per share | $ 0.02 | $ 0.03 | $ 0.05 | $ 0.08 | $ 0.14 |
| Weighted average number of Common Stocks used in computing basic and diluted net loss per share | 10,441,251 | 10,441,251 | 10,441,251 | 10,441,251 | 10,441,251 |
| Other comprehensive loss Available-for-sale investments: | |||||
| Changes in net unrealized loss (gain) | $ (7) | $ (462) | $ 62 | $ (168) | $ 136 |
| Total other comprehensive loss | (7) | (462) | 62 | (168) | 136 |
| Comprehensive loss | $ 237 | $ (109) | $ 601 | $ 713 | $ 1,613 |
| Condensed Statements of Changes in Stockholders' Equity Deficiency - USD ($) $ in Thousands | Total | Shares of Common Stock | Additional paid-in capital | Accumulated deficit | Accumulated other comprehensive income |
| Balance at Dec. 31, 2014 | $ (1,690) | $ 10 | $ 5,494 | $ (7,296) | $ 102 |
| Balance, shares at Dec. 31, 2014 | 10,441,251 | ||||
| Stock based compensation | 19 | 19 | |||
| Unrealized gain from investment in Parent Company | (168) | (168) | |||
| Net loss | (881) | (881) | |||
| Balance at Sep. 30, 2015 | (2,384) | $ 10 | 5,313 | (8,177) | 270 |
| Balance, shares at Sep. 30, 2015 | 10,441,251 | ||||
| Balance at Dec. 31, 2015 | (3,281) | $ 10 | 5,516 | (8,773) | (34) |
| Balance, shares at Dec. 31, 2015 | 10,441,251 | ||||
| Stock based compensation | 3 | 3 | |||
| Unrealized gain from investment in Parent Company | (62) | (62) | |||
| Net loss | (539) | (539) | |||
| Balance at Sep. 30, 2016 | $ (3,879) | $ 10 | $ 5,519 | $ (9,312) | $ (96) |
| Balance, shares at Sep. 30, 2016 | 10,441,251 |
| Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended | ||
| Sep. 30, 2016 | Sep. 30, 2015 | Dec. 31, 2015 | ||
| Cash flows from operating activities: | ||||
| Net loss | $ (539) | $ (881) | $ (1,477) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Decrease (increase) in other accounts receivable | (11) | 59 | 209 | |
| Decrease (increase) in other account payables and accrued expenses | 22 | (37) | 45 | |
| Increase in balance with Related company | 498 | 847 | 1,233 | |
| Depreciation | [1] | 1 | 1 | |
| Stock based compensation | 3 | 19 | 22 | |
| Net cash provided by (used in) operating activities | (27) | 8 | 33 | |
| Cash flows from investing activities: | ||||
| Acquisition of fixed assets | (3) | (3) | ||
| Proceeds from sale of property and equipment | 3 | |||
| Net cash provided by investing activities | (3) | |||
| Change in cash and cash equivalents | (27) | 5 | 33 | |
| Cash and cash equivalents at the beginning of the period | 42 | 9 | 9 | |
| Cash and cash equivalents at the end of the period | $ 15 | $ 14 | $ 42 | |
| [1] | Represents an amount lower than $ 1 | |||
| General | 9 Months Ended |
| Sep. 30, 2016 | |
| General [Abstract] | |
| GENERAL | NOTE 1:- GENERAL a. OphthaliX Inc. (the "Company" or "OphthaliX"), originally incorporated in the State of Nevada on December 10, 1999 under the name Bridge Capital.com Inc., was a nominally capitalized corporation that did not commence its operations until it changed its name to Denali Concrete Management Inc. ("Denali"), in March 2001. Denali was a concrete placement company specializing in providing concrete improvements in the road construction industry. Denali operated primarily in Anchorage, Alaska, placing curb and gutter, sidewalks and retaining walls for state, municipal and military projects. In December 2005, the Company ceased its principal business operations and focused its efforts on seeking a business opportunity, becoming a public shell company in the U.S. Eye-Fite Ltd. ("Eye-Fite" or the "Subsidiary") was founded on June 27, 2011 in contemplation of the execution of a transaction between Can-Fite BioPharma Ltd. (the "Parent company" or "Can-Fite"), a public company in Israel and U.S, and the Company, as further detailed in Note 1b below. The Company and its Subsidiary conduct research and development activities using an exclusive worldwide license for CF101, a synthetic A3 adenosine receptor, or A3AR, agonist (known generically as IB-MECA) solely for the field of ophthalmic diseases after the consummation of the transaction. See also Note 1b2. Following the transaction, Denali changed its name to OphthaliX Inc. and also changed its corporate domicile from Nevada to Delaware. On July 5, 2016, the Company released top-line results from its Phase II clinical trial of CF101 for the treatment of glaucoma. In this trial, no statistically significant differences were found between the CF101 treated group and the placebo group in the primary endpoint of lowering intra ocular pressure (“IOP”). High IOP is a characteristic of glaucoma. CF101 was found to have a favorable safety profile and was well tolerated. In September 2016, the Company’s board of directors and Can-Fite BioPharma Ltd. (“Can-Fite”), the Company’s parent and majority shareholder, consented in writing to, among other things, the voluntary dissolution and liquidation of the Company pursuant to a Plan of Dissolution. In November, 2016, the board of directors of the Company abandoned the voluntary dissolution and liquidation of the Company. Subsequently on November 15, 2016, the Company entered into a non-binding letter of intent with an Israeli company for the acquisition of such company by way of a reverse triangular merger. The proposed reverse merger is subject to signing of definitive transaction documents and the completion of closing conditions. There can be no assurance that the transactions contemplated by the letter of intent will be completed. b. Reverse Recapitalization and related arrangements: 1. Recapitalization: On November 21, 2011 (the "Closing Date"), Can-Fite purchased 8,000,000 shares of the Company’s common stock, par value $ 0.001 per share in exchange for all of the issued and outstanding ordinary shares of Eyefite pursuant to the terms of a stock purchase agreement (the “Purchase Agreement”). As a result, Eyefite became a wholly-owned subsidiary of the Company and Can-Fite became its majority stockholder and a parent. Also on November 21, 2011, the Company issued a warrant to Can-Fite by which Can-Fite has the right, until the earlier of (a) the November 21, 2016 and (b) the closing of the acquisition of the Company by another entity, resulting in the exchange of the Company’s outstanding common shares such that its stockholders prior to such transaction own, directly or indirectly, less than 50% of the voting power of the surviving entity, to convert its right to the Additional Payment (as defined below) into 480,022 shares of Common Stock (subject to adjustment in certain circumstances). The per share exercise price for the shares is $ 5.148. The Company also received 714,922 ordinary shares in Can-Fite, representing approximately 7% of Can-Fite's issued and outstanding share capital as of the Closing Date. On June 17, 2013, the Company sold 268,095 Can-Fite ordinary shares for a total consideration of $511. As of September 30, 2016, the Company holds 446,827 Can-Fite ordinary shares, representing approximately 1.6% of Can-Fite's outstanding share capital. In contemplation of the recapitalization transaction, it was agreed that for every four shares of Common Stock purchased by the New Investors and Can-Fite, they received nine warrants to acquire two share of Common Stock of the Company. The exercise price of such warrants is $ 7.74 per share of Common Stock. The warrants are exercisable for a period of five years from the date of grant. The warrants do not contain nonstandard anti-dilution provisions (see also Note 6b to the consolidated financial statements as of December 31, 2015). The transaction was accounted for as a reverse recapitalization which is outside the scope ASC 805, Business Combinations. Under reverse capitalization accounting, EyeFite is considered the acquirer for accounting and financial reporting purposes, and acquired the assets and assumed the liabilities of the Company. Assets acquired and liabilities assumed are reported at their historical amounts. Consequently, the condensed consolidated financial statements of the Company reflect the operations of the acquirer for accounting purposes together with a deemed issuance of shares, equivalent to the shares held by the former shareholders of the legal acquirer and a recapitalization of the equity of the accounting acquirer. These condensed consolidated financial statements include the accounts of the Company since the effective date of the reverse capitalization and the accounts of EyeFite since inception. 2. License and research and development services from Can-Fite: In connection with the consummation of the recapitalization transaction, the Company and Can-Fite entered into a license agreement, pursuant to which Can-Fite granted EyeFite a sole and exclusive worldwide license for the use of CF101, solely in the field of ophthalmic diseases ("CF101"). EyeFite will be obligated to make to the U.S. National Institutes of Health ("NIH"), with regard to the patents of which are included in the license to EyeFite, for as long as the license agreement between the Company and NIH remains in effect, a nonrefundable minimum annual royalty fee and potential future royalties of 4.0% to 5.5% on net sales. In addition, the Company will be obligated to make certain milestone payments ranging from $25 to $500 upon the achievement of various development milestones for each indication. During 2013, the Company accrued an amount of $75 related to the glaucoma phase II clinical trial. EyeFite will also be required to make payments of 20% of sublicensing revenues, excluding royalties and net of the required milestone payments. Until September 30, 2016, the Company did not reach any milestone or generate revenue that would trigger additional payments to Can-Fite. As of September 30, 2016, the aggregate amount accrued for these milestones payment is $ 175. In addition, following the closing of the recapitalization transaction, Can-Fite, OphthaliX and EyeFite entered into a service agreement (the "Service Agreement"). Pursuant to the terms of the Service Agreement, Can-Fite will manage the research and development activities relating to pre-clinical and clinical studies for the development of the ophthalmic indications of CF101. In consideration for Can-Fite's services, EyeFite will pay to Can-Fite a service fee (consisting of all expenses and costs incurred by Can-Fite plus 15%). In addition, the Company is committed to future additional payments equal to 2.5% of any and all proceeds received by EyeFite relating to the activities regarding the drug (the "Additional Payment"). According to the Service Agreement, Can-Fite will have the right, at any time until November 21, 2016, to convert the Additional Payment into an additional 480,022 shares of Common Stock of the Company for total consideration of $ 2,471 (subject to adjustment in certain circumstances - See also Note 6 to the consolidated financial statements as of December 31, 2015). c. During the nine months ended September 30, 2016 and the year ended December 31, 2015, the Company incurred operating losses amounting to $ 451 and $ 1,385, respectively. In According to management estimates, liquidity resources as of September 30, 2016, will be sufficient to maintain the Company's operations at least through December 31, 2016. The Company's inability to raise funds to conduct its research and development activities will have a severe negative impact on its ability to remain a viable company. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. |
| Unaudited Condensed Financial Statements | 9 Months Ended |
| Sep. 30, 2016 | |
| Unaudited Condensed Financial Statements [Abstract] | |
| UNAUDITED CONDENSED FINANCIAL STATEMENTS | NOTE 2:- UNAUDITED CONDENSED FINANCIAL STATEMENTS The unaudited Condensed Consolidated Financial Statements of OphthaliX Inc. have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheets as of December 31, 2015, included herein was derived from the audited consolidated financial statements for the year ended December 31, 2015. In the opinion of management, all adjustments, including normal recurring accruals, considered necessary for a fair presentation have been included. The results of operations for the nine and three months ended September 30, 2016, are not necessarily indicative of the results that may be expected for the year ending December 31, 2016, or any future period. The information included in this interim report should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Risk Factors," "Quantitative and Qualitative Disclosures About Market Risk," and the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates under different assumptions or conditions. The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2015 are applied consistently in these condensed financial statements .For further information, refer to the consolidated financial statements as of December 31, 2015. |
| Fair Value Measurements | 9 Months Ended |
| Sep. 30, 2016 | |
| Fair Value Measurements [Abstract] | |
| FAIR VALUE MEASUREMENTS | NOTE 3:- FAIR VALUE MEASUREMENTS The Company considers an active market to be one in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis, and views an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Since the quoted market value of the Company’s Common Stock was based on a sporadically traded stock with little volume, the Company's management determined the Company's stock price fair value based on ASC 820 Fair Value Measurement using the income approach assisted by a third party specialist. Consequently, the derivatives are classified within Level 3 because they are valued using valuation techniques. The fair value of the Derivative as of September 30, 2016 and December 31, 2015 amounted to $0, was determined using the binomial option-pricing model. The aforementioned option-pricing model requires a number of assumptions, of which most significant are the expected stock price volatility and the expected term. The Company's investment in Parent Company ordinary shares is measured in accordance with ASC 820, based on the Parent Company's ordinary shares fair value as quoted in the Tel Aviv Stock Exchange. Embedded derivatives are classified within Level 3 because they are valued using valuation techniques. Some of the inputs to these models are unobservable in the market and are significant. The Company's investment in Parent Company ordinary shares is measured in accordance with ASC 820, based on the Parent Company's ordinary shares fair value as quoted in the Tel Aviv Stock Exchange. These securities are classified as available-for-sale securities carried at fair value, with unrealized gains and losses reported as a separate component of shareholders' equity under accumulated other comprehensive loss (income) in the condensed consolidated balance sheets. The assets are classified within Level 1 on the fair value hierarchy. The following table provides information by value level for financial assets and liabilities that are measured at fair value, as defined by ASC 820, on a recurring basis as of September 30, 2016 and December 31, 2015. September 30, 2016 Fair value measurements Description Fair Value Level 1 Level 2 Level 3(1) Investment in Parent Company $ 596 $ 596 $ - $ - Derivative related to Service Agreement *)- - - *)- Total Financial Assets, net $ 596 $ 596 $ - $ - December 31, 2015 Fair value measurements Description Fair Value Level 1 Level 2 Level 3(1) Investment in Parent Company $ 658 $ 658 $ - $ - Derivative related to Service Agreement *)- - - *)- Total Financial Assets, net $ 658 $ 658 $ - $ - *) Represents an amount lower than $1 (1) Fair value measurements using significant unobservable inputs |
| Subsequent Event | 9 Months Ended |
| Sep. 30, 2016 | |
| Subsequent Events [Abstract] | |
| SUBSEQUENT EVENT | NOTE 4:- SUBSEQUENT EVENT 1. On November 10, 2016 the Company's Board of Directors abandoned the voluntary dissolution and liquidation from September 2016. Subsequently, the Company entered into a non-binding letter of intent with an Israeli company for the acquisition of such company by way of a reverse triangular merger. Please see note 1a above. |
| Fair Value Measurements (Tables) | 9 Months Ended |
| Sep. 30, 2016 | |
| Fair Value Measurements [Abstract] | |
| Summary of financial assets and liabilities measured at fair value on recurring basis | September 30, 2016 Fair value measurements Description Fair Value Level 1 Level 2 Level 3(1) Investment in Parent Company $ 596 $ 596 $ - $ - Derivative related to Service Agreement *)- - - *)- Total Financial Assets, net $ 596 $ 596 $ - $ - December 31, 2015 Fair value measurements Description Fair Value Level 1 Level 2 Level 3(1) Investment in Parent Company $ 658 $ 658 $ - $ - Derivative related to Service Agreement *)- - - *)- Total Financial Assets, net $ 658 $ 658 $ - $ - *) Represents an amount lower than $1 (1) Fair value measurements using significant unobservable inputs |
| General (Details) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
| Jun. 17, 2013 | Nov. 21, 2011 | Sep. 30, 2016 | Sep. 30, 2015 | Sep. 30, 2016 | Sep. 30, 2015 | Dec. 31, 2015 | |
| General [Textual] | |||||||
| Common stock, par value | $ 0.001 | $ 0.001 | $ 0.001 | ||||
| Common stock price per share | $ 7.74 | $ 7.74 | |||||
| License agreement, Description | In connection with the consummation of the recapitalization transaction, the Company and Can-Fite entered into a license agreement, pursuant to which Can-Fite granted EyeFite a sole and exclusive worldwide license for the use of CF101, solely in the field of ophthalmic diseases ("CF101"). EyeFite will be obligated to make to the U.S. National Institutes of Health ("NIH"), with regard to the patents of which are included in the license to EyeFite, for as long as the license agreement between the Company and NIH remains in effect, a nonrefundable minimum annual royalty fee and potential future royalties of 4.0% to 5.5% on net sales. | ||||||
| Accrued for milestones payment | $ 175 | $ 175 | |||||
| Service agreement, Description | EyeFite will pay to Can-Fite a service fee (consisting of all expenses and costs incurred by Can-Fite plus 15%). | ||||||
| Interest rate | 3.00% | 3.00% | |||||
| Operating expenses | $ 215 | $ 332 | $ 451 | $ 820 | $ 1,385 | ||
| Deferred payments to Can-Fite | $ 4,188 | $ 4,188 | $ 3,690 | ||||
| Warrant [Member] | |||||||
| General [Textual] | |||||||
| Common stock price per share | $ 7.74 | $ 7.74 | |||||
| DES Phase III clinical trial [Member] | |||||||
| General [Textual] | |||||||
| Accrued for milestones payment | $ 100 | $ 100 | |||||
| Phase II glaucoma Phase II clinical trial [Member] | |||||||
| General [Textual] | |||||||
| Accrued for milestones payment | $ 75 | 75 | |||||
| Maximum [Member] | |||||||
| General [Textual] | |||||||
| Payment for milestone to NIH | 500 | ||||||
| Minimum [Member] | |||||||
| General [Textual] | |||||||
| Payment for milestone to NIH | 25 | ||||||
| Eye-Fite Ltd [Member] | |||||||
| General [Textual] | |||||||
| Issuance of common stock to Can-Fite | $ 2,471 | ||||||
| Issuance of common stock to Can-Fite, shares | 8,000,000 | ||||||
| Common stock, par value | $ 0.001 | ||||||
| Percentage of sublicensing revenues | 20.00% | ||||||
| Interest rate | 2.50% | 2.50% | |||||
| Can-Fite [Member] | |||||||
| General [Textual] | |||||||
| Issuance of common stock to Can-Fite | $ 511 | ||||||
| Issuance of common stock to Can-Fite, shares | 268,095 | 446,827 | |||||
| Common stock, Voting rights | (a) the November 21, 2016 and (b) the closing of the acquisition of the Company by another entity, resulting in the exchange of the Company's outstanding common shares such that its stockholders prior to such transaction own, directly or indirectly, less than 50% of the voting power of the surviving entity, to convert its right to the Additional Payment (as defined below) into 480,022 shares of Common Stock (subject to adjustment in certain circumstances). | ||||||
| Common stock converted into additional payment | 480,022 | ||||||
| Common stock price per share | $ 5.148 | ||||||
| Number of shares exchanged for ordinary shares | 714,922 | ||||||
| Term of warrants | 5 years | ||||||
| Percentage of share capital outstanding | 7.00% | 1.60% | |||||
| Fair Value Measurements (Details) - Recurring [Member] - USD ($) $ in Thousands | Sep. 30, 2016 | Dec. 31, 2015 | |
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||
| Investment in Parent Company | $ 596 | $ 658 | |
| Derivative related to Service Agreement | [1] | ||
| Total Financial Assets, net | 596 | 658 | |
| Level 1 [Member] | |||
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||
| Investment in Parent Company | 596 | 658 | |
| Derivative related to Service Agreement | |||
| Total Financial Assets, net | 596 | 658 | |
| Level 2 [Member] | |||
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||
| Investment in Parent Company | |||
| Derivative related to Service Agreement | |||
| Total Financial Assets, net | |||
| Level 3 [Member] | |||
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||
| Investment in Parent Company | [2] | ||
| Derivative related to Service Agreement | [1],[2] | ||
| Total Financial Assets, net | [2] | ||
| [1] | Represents an amount lower than $ 1 | ||
| [2] | Fair value measurements using significant unobservable inputs | ||
| Fair Value Measurements (Details Textual) - USD ($) $ in Thousands | Sep. 30, 2016 | Dec. 31, 2015 |
| Fair Value Measurements (Textual) | ||
| Fair value of derivative | $ 0 | $ 0 |
